Actively Recruiting
A Study in Healthy Men to Test How Well Different Doses of BI 3821001 Are Tolerated
Led by Boehringer Ingelheim · Updated on 2026-04-30
72
Participants Needed
1
Research Sites
23 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3821001 in healthy male trial participants.
CONDITIONS
Official Title
A Study in Healthy Men to Test How Well Different Doses of BI 3821001 Are Tolerated
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male, healthy according to medical history, physical exam, vital signs, ECG, and lab tests
- Age between 18 to 55 years inclusive
- Body mass index (BMI) between 18.5 to 29.9 kg/m2 inclusive
- Signed informed consent according to ICH-GCP and local laws
You will not qualify if you...
- Any clinically relevant abnormal finding in medical exam, including blood pressure, pulse rate, or ECG
- Repeated systolic blood pressure outside 90 to 140 mmHg, diastolic blood pressure outside 50 to 90 mmHg, or pulse rate outside 50 to 90 bpm
- Any clinically relevant laboratory value outside reference ranges
- Evidence of any clinically relevant concomitant disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CRS Clinical Research Services Berlin GmbH
Berlin, Germany, 13627
Actively Recruiting
Research Team
B
Boehringer Ingelheim
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
10
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here